Last updated: 2026-09-08 14:49:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Atrium Therapeutics, Inc. (RNA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $12.35, with a market capitalization of $242.73M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $11.13 to $73.06. This page covers its latest market performance, valuation, price trends and company information.
$242.73M | |
$14.08 | |
$73.06 | |
$3.43 | |
$14.19 | |
200.43K | |
181.75K | |
-- | |
$73.06 | |
$11.13 | |
-- | |
-- |
Atrium Therapeutics, Inc. (RNA) is currently trading at $12.35 as of 2026-09-08 14:47:00, down 12.96% ($1.84) from the previous close of $14.19
During today's regular trading session, RNA has traded between $3.43 and $73.06, with a trading volume of 200.43K shares. The current price is near the lower end of today's range.
Over the past seven days, Atrium Therapeutics, Inc. (RNA) moved from $13.98 to $12.35, representing a decline of 11.65% ($1.63).
The stock traded between $12.34 and $17.42 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 135.61 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 2.0%
RNA is currently trading at $12.35, placing it 2.0% of the way from its 52-week low of $11.13 to its 52-week high of $73.06. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 391 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Atrium Therapeutics, Inc. (RNA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.